網膜バイオロジクスの世界市場レポート2024

網膜バイオロジクスの市場規模は、今後数年間で急速に成長すると予想されています。 2028年には11.7%の年間複合成長率（CAGR）で396億9,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、治療用途の拡大、個別化医療への傾向、新興市場の成長、生物製剤の強力なパイプライン、業界内の協力とパートナーシップ、政府の取り組みと支援などの要因に起因すると考えられます。予測期間中に予想される注目すべき動向には、非侵襲的送達方法の採用、現実世界の証拠の利用の増加、網膜バイオロジクスの適応症の拡大、規制経路の合理化、患者中心のアウトカムへの注目の高まりなどが含まれます。

予測される糖尿病性眼疾患の有病率の増加により、網膜バイオロジクス市場の成長が促進される見込みです。糖尿病に関連する合併症である糖尿病性眼疾患は、罹患者の視力障害や失明につながります。 網膜バイオロジクスの使用は、より正確で効果的な治療オプションへの有望な手段を提供し、糖尿病性眼疾患に関連する視力喪失の予防において早期介入と改善された結果を可能にします。 2023年 6月に米国医師会が実施した最近の調査研究では、米国の960万人が糖尿病性網膜症に罹患しており、これは糖尿病人口の26.43%を占め、うち184万人が視力を脅かす糖尿病性網膜症を経験しており、そのうちの5.06%を占めていることが明らかになりました。糖尿病の方。

個別化医療に対する需要の高まりにより、網膜バイオロジクス市場の拡大が促進されると予想されます。個人の固有の遺伝子構造に合わせて調整された個別化医療は、より効果的かつ正確なヘルスケア介入を提供します。 網膜バイオロジクスの領域では、個別化医療戦略が採用され、個々の遺伝子および分子プロファイルに基づいて治療アプローチをカスタマイズし、副作用を最小限に抑えながら有効性を最適化します。 2023年1月の個別化医療連合のデータによると、2022年に食品医薬品局の医薬品評価研究センター（CDER）によって承認された37の新しい分子実体（NME）のうち、約34％（12のNME）が以下に分類されていることが明らかになりました。個別化医療連合による個別化医療。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の網膜生物製剤市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 血管内皮増殖因子（VEGF）-Aアンタゴニスト
• 腫瘍壊死因子（TNF）-A阻害剤
• 世界の網膜生物製剤市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 黄斑変性症
• 糖尿病性網膜症
• ぶどう膜炎
• 糖尿病性黄斑浮腫
• その他の適応症
• 世界の網膜生物製剤市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 薬局
• 専門クリニック
• オンライン薬局
• その他の流通チャネル

第7章 地域および国の分析

• 世界の網膜生物製剤市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の網膜生物製剤市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 網膜生物製剤市場の競合情勢
• 網膜生物製剤市場の企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck &Co Inc
  • AbbVie Inc.
  • Bayer AG

第31章 その他の大手および革新的な企業

• Janssen Biotech
• Novartis AG
• Fresenius SE
• AstraZeneca plc
• Boehringer Ingelheim International GmbH.
• Amgen Inc
• Teva Pharmaceuticals Industries Ltd.
• Bristol-Myers Squibb
• Regeneron Pharmaceuticals Inc
• Sun Pharmaceutical Industries Ltd.
• Sanofi Genzyme
• Bausch &Lomb
• Santen Pharmaceutical Co. Ltd.
• Swedish Orphan Biovitrum
• Ocular Therapeutix

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Retinal biologics refer to bioengineered macromolecules that are implanted inside the eyes to treat chronic retinal diseases. These highly precise compounds target inflammatory mediators and are used in the treatment of various inflammatory, corneal, and retinal medical conditions.

The main types of retinal biologics include vascular endothelial growth factor (VEGF)-A antagonists and tumor necrosis factor (TNF)-A inhibitors. A VEGF-A antagonist is a substance that inhibits the activity of vascular endothelial growth factor, a potent angiogenic factor and an essential growth factor for vascular endothelial cells. These biologics are administered for various indications, including macular degeneration, diabetic retinopathy, uveitis, diabetic macular edema, and others. They are typically available in hospitals, pharmacies, specialty clinics, online pharmacies, and other healthcare facilities.

The retinal biologics market research report is one of a series of new reports from The Business Research Company that provides retinal biologics market statistics, including retinal biologics industry global market size, regional shares, competitors with a retinal biologics market share, detailed retinal biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the retinal biologics industry. This retinal biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The retinal biologics market size has grown rapidly in recent years. It will grow from $22.48 billion in 2023 to $25.45 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The increase observed in the historical period can be attributed to factors such as the increased incidence of retinal disorders, an aging population, growing awareness and early diagnosis of retinal conditions, the evolution of healthcare infrastructure, and a rise in healthcare expenditure.

The retinal biologics market size is expected to see rapid growth in the next few years. It will grow to $39.69 billion in 2028 at a compound annual growth rate (CAGR) of 11.7%. The anticipated growth in the forecast period can be attributed to factors such as expanding therapeutic applications, the trend towards personalized medicine, growth in emerging markets, a strong pipeline of biologics, collaborations and partnerships within the industry, and government initiatives and support. Noteworthy trends expected during the forecast period include the adoption of non-invasive delivery methods, increased utilization of real-world evidence, expansion of indications for retinal biologics, streamlining of regulatory pathways, and a growing focus on patient-centric outcomes.

The anticipated rise in the prevalence of diabetic eye disease is poised to drive the growth of the retinal biologics market. Diabetic eye disease, a complication associated with diabetes, leads to vision impairment and blindness in affected individuals. The use of retinal biologics presents a promising avenue for more precise and effective treatment options, allowing for early intervention and improved outcomes in preventing vision loss linked to diabetic eye disease. A recent research study conducted by the American Medical Association in June 2023 revealed that diabetic retinopathy impacted 9.60 million individuals in the United States, constituting 26.43% of the diabetic population, with 1.84 million people experiencing vision-threatening diabetic retinopathy, accounting for 5.06% of those with diabetes.

The growing demand for personalized medicine is anticipated to fuel the expansion of the retinal biologics market. Personalized medicine, tailored to an individual's unique genetic makeup, offers more effective and precise healthcare interventions. In the realm of retinal biologics, personalized medicine strategies are employed to customize treatment approaches based on individual genetic and molecular profiles, optimizing efficacy while minimizing adverse effects. Data from the Personalized Medicine Coalition in January 2023 revealed that out of the 37 new molecular entities (NMEs) approved by the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) in 2022, approximately 34% (12 NMEs) are classified as personalized medicines by the Personalized Medicine Coalition.

A prominent trend gaining traction in the retinal biologics market is product innovation. Leading companies in this market are actively engaged in the development of innovative products to enhance their market position and gain a competitive edge. Notably, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, announced in May 2023 that the U.S. Food and Drug Administration had accepted the company's supplemental biologics license application (sBLA) for Vabysmo (faricimab), designed for the treatment of macular edema following retinal vein occlusion (RVO). Vabysmo is a bispecific antibody that has demonstrated early and persistent visual improvement, achieving the primary endpoint of non-inferiority to aflibercept. This product marks a significant advancement as the first bispecific antibody approved for the eye to treat 'wet' age-related macular degeneration and diabetic macular edema.

Strategic partnerships are a prominent approach adopted by major companies in the retinal biologics market to fortify their market presence and offer innovative solutions. Biogen Inc., a U.S.-based biotechnology company, entered into a strategic partnership with Samsung Bioepis Co., Ltd., a South Korean biotechnology company, in June 2022. This collaboration led to the launch of BYOOVIZ, a biosimilar for retinal vascular disorders. BYOOVIZ holds potential for substantial cost savings within the U.S. healthcare system while expanding access for patients with retinal disorders.

In January 2023, Coherus BioSciences Inc., a U.S.-based biosimilar therapeutics company, secured exclusive commercialization rights to FYB203, a biosimilar candidate of Eylea (aflibercept), from Klinge Biopharma GmbH in the United States. This strategic acquisition expands Coherus' market opportunity in the anti-VEGF medications segment, supporting mid-to-long-term growth and revenue potential. Klinge Biopharma GmbH is a Germany-based firm specializing in anti-VEGF medications.

Major companies operating in the retinal biologics market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., AbbVie Inc., Bayer AG, Janssen Biotech, Novartis AG, Fresenius SE, AstraZeneca PLC, Boehringer Ingelheim International GmbH., Amgen Inc., Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Sanofi Genzyme, Bausch & Lomb, Santen Pharmaceutical Co. Ltd., Swedish Orphan Biovitrum, Ocular Therapeutix, Alimera Sciences, Adverum Biotechnologies Inc., MeiraGTx Limited, Oxurion NV, Graybug Vision Inc., Kodiak Sciences Inc., Clearside Biomedical Inc., UCBCares, Allergan PLC, Genentech Inc., Iveric bio Inc., Neurotech Pharmaceuticals Inc., Opthea Limited

North America was the largest region in the retinal biologics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the retinal biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The retinal biologics market consists of sales of ranibizumab, aflibercept, and brolucizumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Retinal Biologics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on retinal biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for retinal biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The retinal biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist; Tumor Necrosis Factor (TNF)-A Inhibitor
• 2) By Indication: Macular Degeneration; Diabetic Retinopathy; Uveitis; Diabetic Macular Edema; Other Indications
• 3) By Distribution Channel: Hospitals; Pharmacies; Specialty Clinics; Online Pharmacies; Other Distribution Channels
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co Inc; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Retinal Biologics Market Characteristics

3. Retinal Biologics Market Trends And Strategies

4. Retinal Biologics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Retinal Biologics Market Size and Growth

• 5.1. Global Retinal Biologics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Retinal Biologics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Retinal Biologics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Retinal Biologics Market Segmentation

• 6.1. Global Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Vascular Endothelial Growth Factor (VEGF)-A Antagonist
• Tumor Necrosis Factor (TNF)-A Inhibitor
• 6.2. Global Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Macular Degeneration
• Diabetic Retinopathy
• Uveitis
• Diabetic Macular Edema
• Other Indications
• 6.3. Global Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Pharmacies
• Specialty Clinics
• Online Pharmacies
• Other Distribution Channels

7. Retinal Biologics Market Regional And Country Analysis

• 7.1. Global Retinal Biologics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Retinal Biologics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Retinal Biologics Market

• 8.1. Asia-Pacific Retinal Biologics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Retinal Biologics Market

• 9.1. China Retinal Biologics Market Overview
• 9.2. China Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Retinal Biologics Market

• 10.1. India Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Retinal Biologics Market

• 11.1. Japan Retinal Biologics Market Overview
• 11.2. Japan Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Retinal Biologics Market

• 12.1. Australia Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Retinal Biologics Market

• 13.1. Indonesia Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Retinal Biologics Market

• 14.1. South Korea Retinal Biologics Market Overview
• 14.2. South Korea Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Retinal Biologics Market

• 15.1. Western Europe Retinal Biologics Market Overview
• 15.2. Western Europe Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Retinal Biologics Market

• 16.1. UK Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Retinal Biologics Market

• 17.1. Germany Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Retinal Biologics Market

• 18.1. France Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Retinal Biologics Market

• 19.1. Italy Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Retinal Biologics Market

• 20.1. Spain Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Retinal Biologics Market

• 21.1. Eastern Europe Retinal Biologics Market Overview
• 21.2. Eastern Europe Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Retinal Biologics Market

• 22.1. Russia Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Retinal Biologics Market

• 23.1. North America Retinal Biologics Market Overview
• 23.2. North America Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Retinal Biologics Market

• 24.1. USA Retinal Biologics Market Overview
• 24.2. USA Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Retinal Biologics Market

• 25.1. Canada Retinal Biologics Market Overview
• 25.2. Canada Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Retinal Biologics Market

• 26.1. South America Retinal Biologics Market Overview
• 26.2. South America Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Retinal Biologics Market

• 27.1. Brazil Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Retinal Biologics Market

• 28.1. Middle East Retinal Biologics Market Overview
• 28.2. Middle East Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Retinal Biologics Market

• 29.1. Africa Retinal Biologics Market Overview
• 29.2. Africa Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Retinal Biologics Market Competitive Landscape And Company Profiles

• 30.1. Retinal Biologics Market Competitive Landscape
• 30.2. Retinal Biologics Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche Ltd
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co Inc
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AbbVie Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bayer AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Retinal Biologics Market Other Major And Innovative Companies

• 31.1. Janssen Biotech
• 31.2. Novartis AG
• 31.3. Fresenius SE
• 31.4. AstraZeneca plc
• 31.5. Boehringer Ingelheim International GmbH.
• 31.6. Amgen Inc
• 31.7. Teva Pharmaceuticals Industries Ltd.
• 31.8. Bristol-Myers Squibb
• 31.9. Regeneron Pharmaceuticals Inc
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Sanofi Genzyme
• 31.12. Bausch & Lomb
• 31.13. Santen Pharmaceutical Co. Ltd.
• 31.14. Swedish Orphan Biovitrum
• 31.15. Ocular Therapeutix

32. Global Retinal Biologics Market Competitive Benchmarking

33. Global Retinal Biologics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Retinal Biologics Market

35. Retinal Biologics Market Future Outlook and Potential Analysis

• 35.1 Retinal Biologics Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Retinal Biologics Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Retinal Biologics Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer